Newport Trust Company’s AbbVie ABBV Stock Holding History

Newport Trust Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,215,146	Closed	-$119M	–	50
2020 Q2	$119M	Buy	+1,215,146	New	+$107M	0.44%	23

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Newport Trust Company's ABBV Position: Q3 2020 in Review

Newport Trust Company sold out of AbbVie (ABBV) in Q3 2020, closing a stake of 1,215,146 shares — an estimated $119M sold.

Newport Trust Company first reported a position in ABBV in Q2 2020 and held it in 1 quarter. The position peaked at $119M in Q2 2020. 2,366 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

Newport Trust Company reported no remaining AbbVie position as of Q3 2020 after selling out during the quarter.
Newport Trust Company sold 1,215,146 AbbVie shares in Q3 2020, an estimated $119M.
Newport Trust Company first reported a position in AbbVie in Q2 2020 and held it in 1 quarter.
Newport Trust Company's AbbVie position peaked at $119M in Q2 2020.
2,366 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on Newport Trust Company's 13F filing for Q3 2020, filed 9 Nov 2020.